Posted Significant FDA Clinical Trial Results for GTB-3550 TriKE™ in AML and MDS Patients
Established GMP Manufacturing Partnership with Cytovance
Initiated Manufacturing of Additional Solid Tumor TriKE™ for Programs in Lung, Breast, Ovarian and Gastrointestinal Cancers, in preparation for FDA Clinical Trials
Brought in Accomplished Board of Directors
Successful NASDAQ Listing and Financing of $28.7 Million Public Offering Covering Two Years of Capital Requirements, Now Leaving the Company with Over $30 Million in the Bank
PR Newswire
BEVERLY HILLS, Calif., April 19, 2021
